Akari Therapeutics Plc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
AKTX$7.66+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| (In thousands, except share and per share amounts) | 2024 | 2023* |
| ASSETS | ||
| Current assets: | ||
| Cash | $1,310 | $3,845 |
| Prepaid expenses | 1,230 | 299 |
| Other current assets | 232 | 197 |
| Total current assets | 2,772 | 4,341 |
| Patent acquisition costs, net | — | 14 |
| Total assets | $2,772 | $4,355 |
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $3,208 | $1,671 |
| Accrued expenses | 1,530 | 1,566 |
| Warrant liability | 604 | 1,253 |
| Other current liabilities | 983 | 94 |
| Total current liabilities | 6,325 | 4,584 |
| Commitments and contingencies (Note 9) | ||
| Shareholders’ deficit: | ||
| Share capital of $0.0001 par value | ||
| Authorized: 45,122,321,523 ordinary shares at March 31, 2024 and December 31, 2023, respectively; issued and outstanding: 15,973,121,298 and 13,234,315,298 at March 31, 2024 and December 31, 2023, respectively | 1,598 | 1,324 |
| Additional paid-in capital | 176,443 | 174,754 |
| Capital redemption reserve | 52,194 | 52,194 |
| Accumulated other comprehensive loss | (761) | (1,040) |
| Accumulated deficit | (233,027) | (227,461) |
| Total shareholders’ deficit | (3,553) | (229) |
| Total liabilities and shareholders' deficit | $2,772 | $4,355 |
———————
- The condensed balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.